ELION THERAPEUTICS

Serial Number 98301402
Registration 7757756
700

Registration Progress

Application Filed
Dec 6, 2023
Under Examination
Approved for Publication
Feb 25, 2025
Published for Opposition
Feb 25, 2025
Registered
Apr 15, 2025

Trademark Image

ELION THERAPEUTICS

Basic Information

Serial Number
98301402
Registration Number
7757756
Filing Date
December 6, 2023
Registration Date
April 15, 2025
Published for Opposition
February 25, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 15, 2025
Registration
Registered
Classes
042

Rights Holder

ELION THERAPEUTICS, INC.

03
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010

Ownership History

Sfunga Therapeutics, Inc.

Original Applicant
03
New York, NY

ELION THERAPEUTICS, INC.

New Owner Before Publication #1
03
NEW YORK, NY

ELION THERAPEUTICS, INC.

Owner at Publication
03
NEW YORK, NY

ELION THERAPEUTICS, INC.

Original Registrant
03
NEW YORK, NY

Legal Representation

Attorney
J. Dickson Phillips III

USPTO Deadlines

Next Deadline
1899 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250415)
Due Date
April 15, 2031
Grace Period Ends
October 15, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

22 events
Date Code Type Description Documents
Apr 15, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 15, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Feb 25, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 25, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 19, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 4, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 6, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 6, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 6, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 3, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Sep 3, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Jul 5, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 5, 2024 IUAA P USE AMENDMENT ACCEPTED Loading...
Jul 5, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
May 23, 2024 AUPC I AMENDMENT TO USE PROCESSING COMPLETE Loading...
May 23, 2024 IUAF S USE AMENDMENT FILED Loading...
May 23, 2024 EAAU I TEAS AMENDMENT OF USE RECEIVED Loading...
May 16, 2024 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Mar 3, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 6, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Pharmaceutical research and development; Research and development of medications administered by a healthcare professional in a healthcare setting for systemic fungal infections or invasive fungal disease; Providing scientific information on the disease state and treatment of invasive fungal infections and invasive fungal disease; Providing a website featuring scientific information about the disease state and treatment of invasive fungal infections and invasive fungal disease
First Use Anywhere: Jan 10, 2024
First Use in Commerce: Jan 10, 2024

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"